Loading
A phase 1/2 trial of Pembrolizumab in ovarian cancer and melanoma, run by BioInvent International AB, now recruiting.
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) is a phase 1/2 interventional study registered as NCT04752826 by BioInvent International AB, with 176 participants planned, started 2021-01-25 and due to reach its primary completion in 2026-12-31. Interventions recorded: BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection. Conditions listed: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma. No results are recorded here; the registry entry is the source.
Shares BioInvent International, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares BioInvent International, Pembrolizumab, Immune checkpoint inhibitors.